Covant Therapeutics

10:30 AM - 10:45 AM (EDT), Thursday, June 8, 2023 ・ Session Room 104A
Covant’s mission is to treat diseases with transformative therapeutics using covalency to modulate the most significant drug targets at unprecedented depth, breadth and speed.
Nature regulates proteins by imprinting post-translational modifications on specific amino acids. We emulate biology by targeting those specific sites with covalent small molecules.
To translate our discoveries and maximize our probability of success, we focus on residues accessible and reactive in native disease-relevant context. We use our state-of-the-art chemoproteomics platform, and deep learning algorithms to broaden the targetable protein and amino acid space. We have built an industry leading proprietary Reactome Atlas, with deep sequence coverage for thousands of proteins, and a proprietary library, with molecules bearing both clinically validated and novel reactive warheads. Combining these with our structural proteomics and computational workflows, we enable fast prosecution of programs.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
ADAR1 inhibitor
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Placeholder Photo
Chief Scientific Officer
Covant Therapeutics